Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5.

Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, Harousseau JL, Issa JP, Hermouet S.

Leukemia. 2010 May;24(5):1069-73. doi: 10.1038/leu.2010.23. Epub 2010 Feb 25. No abstract available.

PMID:
20182460
2.

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F.

Shide K, Shimoda HK, Kumano T, Karube K, Kameda T, Takenaka K, Oku S, Abe H, Katayose KS, Kubuki Y, Kusumoto K, Hasuike S, Tahara Y, Nagata K, Matsuda T, Ohshima K, Harada M, Shimoda K.

Leukemia. 2008 Jan;22(1):87-95. Epub 2007 Nov 22.

PMID:
18033315
3.

Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.

Grimwade LF, Happerfield L, Tristram C, McIntosh G, Rees M, Bench AJ, Boyd EM, Hall M, Quinn A, Piggott N, Scorer P, Scott MA, Erber WN.

Br J Haematol. 2009 Nov;147(4):495-506. doi: 10.1111/j.1365-2141.2009.07870.x. Epub 2009 Aug 31.

PMID:
19747364
4.

Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation.

Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, Maciejewski JP, Hsi ED.

Am J Surg Pathol. 2007 Feb;31(2):233-9.

PMID:
17255768
5.

Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.

Hoermann G, Cerny-Reiterer S, Herrmann H, Blatt K, Bilban M, Gisslinger H, Gisslinger B, Müllauer L, Kralovics R, Mannhalter C, Valent P, Mayerhofer M.

FASEB J. 2012 Feb;26(2):894-906. doi: 10.1096/fj.11-193078. Epub 2011 Nov 3.

PMID:
22051730
6.

STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.

Funakoshi-Tago M, Tago K, Abe M, Sonoda Y, Kasahara T.

J Biol Chem. 2010 Feb 19;285(8):5296-307. doi: 10.1074/jbc.M109.040733. Epub 2009 Dec 22.

7.

A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera.

Ma AC, Fan A, Ward AC, Liongue C, Lewis RS, Cheng SH, Chan PK, Yip SF, Liang R, Leung AY.

Exp Hematol. 2009 Dec;37(12):1379-1386.e4. doi: 10.1016/j.exphem.2009.08.008. Epub 2009 Sep 20.

PMID:
19772888
8.

A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.

Marty C, Lacout C, Droin N, Le Couédic JP, Ribrag V, Solary E, Vainchenker W, Villeval JL, Plo I.

Leukemia. 2013 Nov;27(11):2187-95. doi: 10.1038/leu.2013.102. Epub 2013 Apr 5.

PMID:
23558526
9.

Deacetylase activity is required for STAT5-dependent GM-CSF functional activity in macrophages and differentiation to dendritic cells.

Sebastián C, Serra M, Yeramian A, Serrat N, Lloberas J, Celada A.

J Immunol. 2008 May 1;180(9):5898-906.

10.

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.

Baffert F, Régnier CH, De Pover A, Pissot-Soldermann C, Tavares GA, Blasco F, Brueggen J, Chène P, Drueckes P, Erdmann D, Furet P, Gerspacher M, Lang M, Ledieu D, Nolan L, Ruetz S, Trappe J, Vangrevelinghe E, Wartmann M, Wyder L, Hofmann F, Radimerski T.

Mol Cancer Ther. 2010 Jul;9(7):1945-55. doi: 10.1158/1535-7163.MCT-10-0053. Epub 2010 Jun 29.

11.
12.

Endothelial progenitor cells are clonal and exhibit the JAK2(V617F) mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms.

Teofili L, Martini M, Iachininoto MG, Capodimonti S, Nuzzolo ER, Torti L, Cenci T, Larocca LM, Leone G.

Blood. 2011 Mar 3;117(9):2700-7. doi: 10.1182/blood-2010-07-297598. Epub 2011 Jan 6.

13.

Characterization of murine JAK2V617F-positive myeloproliferative disease.

Bumm TG, Elsea C, Corbin AS, Loriaux M, Sherbenou D, Wood L, Deininger J, Silver RT, Druker BJ, Deininger MW.

Cancer Res. 2006 Dec 1;66(23):11156-65.

14.

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.

Pietra D, Li S, Brisci A, Passamonti F, Rumi E, Theocharides A, Ferrari M, Gisslinger H, Kralovics R, Cremonesi L, Skoda R, Cazzola M.

Blood. 2008 Feb 1;111(3):1686-9. Epub 2007 Nov 5.

15.

Tyk2 mutation homologous to V617F Jak2 is not found in essential thrombocythaemia, although it induces constitutive signaling and growth factor independence.

Shide K, Shimoda K, Kamezaki K, Kakumitsu H, Kumano T, Numata A, Ishikawa F, Takenaka K, Yamamoto K, Matsuda T, Harada M.

Leuk Res. 2007 Aug;31(8):1077-84. Epub 2006 Sep 29.

PMID:
17011030
16.

The acute lymphoblastic leukemia-associated JAK2 L611S mutant induces tumorigenesis in nude mice.

Funakoshi-Tago M, Tago K, Sumi K, Abe M, Aizu-Yokota E, Oshio T, Sonoda Y, Kasahara T.

J Biol Chem. 2009 May 8;284(19):12680-90. doi: 10.1074/jbc.M808879200. Epub 2009 Mar 16.

17.

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M.

Blood. 2008 Apr 1;111(7):3751-9. doi: 10.1182/blood-2007-07-102186. Epub 2008 Jan 23.

18.

Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.

Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, Vanelli L, Arcaini L, Burcheri S, Malcovati L, Lazzarino M, Cazzola M.

Blood. 2006 May 1;107(9):3676-82. Epub 2005 Dec 22.

19.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.

Orv Hetil. 2006 Nov 12;147(45):2175-9. Hungarian.

PMID:
17402211
20.

[The quantitative evaluation of mutation V617F of gene JAK2 under chronic myeloproliferative diseases].

Abdullaeva AO, Glinshchikova OA, Suslova SA, Shadieva NKh, Kolosova LIu, Meshcheriakova LM, Vakhrusheva MV, Sudarikov AB.

Klin Lab Diagn. 2012 Jul;(7):24-8. Russian.

PMID:
22988798

Supplemental Content

Support Center